Infectious Disease Therapies Research and Innovation Act of 2022

Bill 117 HR 7515, also known as the Infectious Disease Therapies Research and Innovation Act of 2022, aims to address the ongoing challenges posed by infectious diseases through increased research and innovation. The bill focuses on developing new therapies and treatments to combat infectious diseases, with a particular emphasis on emerging and drug-resistant pathogens.

Key provisions of the bill include the establishment of a grant program to support research and development of new therapies for infectious diseases. This program will provide funding to researchers and institutions working on innovative treatments, with a focus on addressing gaps in current treatment options.

Additionally, the bill calls for the creation of a task force to coordinate efforts across government agencies and private sector partners to accelerate the development and approval of new infectious disease therapies. This task force will work to streamline regulatory processes and promote collaboration among stakeholders in the field. Overall, the Infectious Disease Therapies Research and Innovation Act of 2022 seeks to enhance the nation's ability to respond to infectious disease threats by fostering research and innovation in the development of new therapies. By investing in cutting-edge treatments and promoting collaboration among key stakeholders, the bill aims to improve public health outcomes and protect against the spread of infectious diseases.